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ABSTRACT
Background: Nerve growth factor (NGF) promotes neural recovery after experimental traumatic brain
injury (TBI) supporting neuronal growth, differentiation and survival of brain cells and up-regulating the
neurogenesis-associated protein Doublecortin (DCX). Only a few studies reported NGF administration in
paediatric patients with severe TBI.
Methods: A four-year-old boy in a persistent unresponsive wakefulness syndrome (UWS) was treated
with intranasal murine NGF administration 6 months after severe TBI. The patient received four cycles of
intranasal NGF (0.1 mg/kg, twice a day for 10 consecutive days).
Results: NGF administration improved functional [Positron Emission Tomography/Computed
Tomography (PET/CT); Single photon emission/Computed Tomography (SPECT/CT) and Magnetic
Resonance Imaging (MRI)] assessment, electrophysiological [Electroencephalogram (EEG) and Visual
Evoked Potential (VEP)] studies and clinical conditions. He showed improvements in voluntary move-
ments, facial mimicry, phonation, attention and verbal comprehension, ability to cry, cough reflex, oral
motility, feeding capacity, and bowel and urinary functions. After NGF administration, raised levels of
both NGF and DCX were found in the cerebrospinal fluid of the patient. No side effects were reported.
Conclusions: Although further studies are needed for better understanding the neuroprotective role of
this neurotrophin, intranasal NGF administration appears to be a promising and safe rescuing strategy
treatment in children with neurological impairment after TBI.
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Abbreviations
● BBB: Blood–Brain Barrier
● BDNF: Brain-Derived Neurotrophic Factor
● BFCN: Basal Forebrain Cholinergic Neurons
● CNS: Central Nervous System
● CSF: Cerebrospinal Fluid
● DCX: Doublecortin
● EEG: Electroencephalogram
● GCS: Glasgow Coma Scale
● HIBI: Hypoxic-Ischaemic Brain Injury
● MAD: Mucosal Atomiser Device
● NGF: Nerve Growth Factor
● MRI: Magnetic Resonance Imaging
● PET/CT: Positron Emission Tomography/Computed
Tomography
● PICU: Paediatric Intensive Care Unit
● SPECT/CT: Single-Photon Emission/Computed
Tomography
● SSEP: Somatosensory Evoked Potentials
● TBI: Traumatic Brain Injury
● TrkA: Tyrosine receptor Kinase A
● VEP: Visual Evoked Potential
Introduction
Traumatic brain injury (TBI) is a common cause of morbidity
and mortality among children and young adults in developed
countries. In 2010, the Centers for Disease Control and
Prevention (CDC) estimated that TBI accounted for approxi-
mately 2.5 million emergency department (ED) visits and
hospitalizations in the USA, either as an isolated injury or in
combination with other injuries (1).
In particular, the rates of TBI-related ED visits increased for
all age groups from the period of 2001–2002 to 2009–2010. The
rates of TBI-related ED visits increased the most for children
4 years of age and younger. Children 0–4 years of age had the
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highest rates of any age group, typically with almost twice the
rate of those in the next highest age group (15–24-year-olds) (2).
The outcome of TBI patients depends on the primary
injury, for instance, the direct insult of neuronal, glial and
vascular cells, and the secondary injury, which may include
reperfusion, hypoxia, oedema and ischaemia (3). Secondary
brain damage frequently causes the loss of cerebral neurons
and can be associated with a progressive decrease in cognitive
and motor functions. Children suffering from severe TBI
show long-term sequelae, more pronounced in behavioural,
neurological and neuropsychological functions (4). Currently,
no effective therapies can restore neuronal loss or produce
substantial clinical improvement in this kind of patients.
Nerve growth factor (NGF) is a neurotrophin supporting
the neuronal growth, differentiation and survival (5) of brain
cells and allows neurites to sprout, restoring the function of
injured neurons (6). Experimental animal studies have shown
that intraventricular NGF administration prevents the loss of
phenotype and preserves cholinergic neurons after severe TBI,
by increasing the synthesis of choline acetyltransferase and
preventing atrophy of basal forebrain cholinergic neurons (7).
Intraventricular NGF infusion has also been shown to reduce
the malacic areas in the brain, improving cerebral perfusion
and cognitive functions in children with severe hypoxic-
ischaemic brain injury (4). However, little is known about
the neuroprotective role of NGF in the damaged brain.
Some data indicate that NGF triggers the migration and
proliferation of endothelial cells and enhances the functional
maturation of newly assembled vessels and neuronal precur-
sors (8,9). Most of these neuronal precursors express mor-
phological markers of striatum projection neurons, such as
the Doublecortin (DCX) (10). DCX contributes to neuronal
repair by stabilizing microtubules in neuronal cells and repre-
sents a specific marker for tracking the migration of new
neurons into the injured sites of the brain (11). An increase
of DCX expression has been demonstrated following intra-
ventricular brain-derived neurotrophic factor (BDNF) and
NGF administration (12). Despite the promising results
obtained with NGF treatment, the poor permeability of the
blood–brain barrier (BBB) when NGF is injected systemically
(13) and the invasiveness of intraventricular administration
represent the major obstacles to the development of NGF-
based clinical trials. To the best of our knowledge, at least one
clinical trial is registered and actually active in which adult
patients with TBI should have been treated with intranasal
NGF (14), but no results have been published yet. The intra-
nasal delivery of NGF to the brain could represent a non-
invasive and safe route to achieve a significant and effective
concentration of NGF in selected brain areas (15). Given
intranasally in rats with experimental TBI, NGF has been
shown to reduce brain oedema and improve motor function
(16,17). Indeed, the olfactory pathway is a promising route for
the direct delivery of NGF to the central nervous system
(CNS), utilizing the potential transport pathway from the
nose to the brain through the olfactory region with minimal
systemic exposure (18,19). According to these hypotheses, the
aim of this case study is to investigate the effects of intranasal
NGF administration on brain functions in a child with serious
motor and cognitive impairment after severe TBI.
Case Report
A four-year-old boy, 20 kg body weight, was admitted to the
Pediatric Intensive Care Unit (PICU) after a cardiac arrest
following a severe TBI secondary to a car accident. He under-
went immediate resuscitation manoeuvres and tracheal intu-
bation. After 7 minutes of cardiopulmonary arrest, the patient
returned to a spontaneous circulation and was transported to
the PICU, where the neurologic examination showed a
Glasgow Coma Scale (GCS) of 4. Total body CT scan showed
blood share in the lateral ventricles, deep and diffuse haemor-
rhagic petechiae, occipital fracture, left pulmonary contusion
and bilateral pleural effusion with flap. Brain MRI showed
multiple frontal and temporal cortico-subcortical biemisferic
haemorrhagic contusions, signs of axonal distraction at brain-
stem and at the splenium of the corpus callosum. Bilateral
areas of increased T2 signal involving basal ganglia consistent
with anoxic injury component were also detected. The spine
MRI demonstrated severe oedematous spinal cord injury at
the C1–C2 level. According to the post-resuscitation cardiac
arrest management protocol established in our hospital, a 24-
hour mild therapeutic hypothermia (34°C) was started. After
4 days the sedation was stopped and the child showed eye
opening. A complete failure of respiratory trigger and a tetra-
plegia were detected, due to spinal cord and brain stem lesion,
so the patient underwent tracheostomy and a placement of a
gastrostomy tube. At day 28 after TBI the child showed a lack
of swallowing, inability to speech, reflex movements without
response to command and minimally conscious state in the
presence of wakefulness [unresponsive wakefulness syndrome
(UWS)] (20–22). Communication was possible only through
eye movements and mouth opening. Somatosensory evoked
potentials (SSEP) showed a marked distress functional tract of
the upper limbs, presumably related to the damage at the
brainstem and cervical spinal cord. Six months after TBI,
the child was transferred to the department of Neuro-rehabi-
litation Unit for an overall rehabilitative management.
Neurological and functional examination
The neurological examination at the admission in Neuro-
rehabilitation Unit showed an alert and conscious child with
tetraplegia, severe communicative and neuropsychological
impairment, and complete dysphagia. Spinal cord cervical
injury resulted in impaired respiration requiring full-time
mechanical ventilation through tracheostomy. The patient
was fed only by gastrostomy. The child also lost bladder and
bowel functions, due to the level of brainstem and spinal cord
lesion. After an initial hypotonic state, increased muscle tone
was observed, especially in the lower limbs. An oral-motor
dyspraxia was also detected. Tetraplegia resulted in loss of
function of the limbs, as well as the trunk, and pelvic organs.
An accurate neurological assessment was difficult to obtain in
view of the child’s age, concomitant brain and spinal cord
injuries, and severe disability in communication. Owing to
these problems, a sensorimotor score was obtained using
‘ASIA-IMSOP Classification’, which revealed loss of skin sen-
sitiveness and movement below the C2 level. The ASIA
Impairment Scale of ‘A’ confirmed a complete spinal cord
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lesion (23). Only reflexed pattern movements were present.
EEG recordings showed a theta background activity with a
poor electric organization. Functional rating was performed
using Spinal Cord Independence Measure (SCIM), Version III
(24), reporting a final score of 11 (from 0 to 100, in which 100
represents the total independence in movements). A targeted
management of spasticity with botulinum toxin injection in
specific muscle groups was performed without any improve-
ment. The patient also received numerous physiotherapy
cycles without any evidence of improvement in his commu-
nicative and cognitive skills and or any of his motor functions.
Intranasal NGF administration
Six months after TBI, in view of the persistent severe UWS and
tetraplegia and lacking any other feasible therapeutic approach
(after proper and standardized medical, neuro-intensive and
rehabilitative care), treatment with intranasal murine NGF
administration was taken into consideration. This treatment
was approved by our University’s Ethical Board and by the
child’s parents, who provided written informed consent. The
child received a total of four cycles of intranasal NGF. Each
treatment was repeated at one-month intervals. In each cycle
the NGF was administered at the dose of 0.1 mg/kg (2 mg of
NGF diluted in 20 mL of saline solution) through a mucosal
atomiser device (MAD), used to deliver medication via a fine
spray in both nostrils of the nasal cavity. In each treatment,
0.5 mL of the diluted solution was administered in each nostril
(0.5 mL containing about 0.05 mg of NGF twice a day for 10
consecutive days = 0.2 mg of NGF/daily). This amount is con-
sidered sufficient to reach and stimulate NGF receptors, mainly
Tyrosine receptor kinase A (TrkA), in most cerebral cholinergic
and serotoninergic areas of the brain, as previously reported in
the literature (25,26). Before NGF administration, the nostrils
were washed with 1 mL of saline solution, successively aspirated,
to avoid any interference with the drug absorption (for the
isolation and intranasal NGF preparation, see Supplementary
Materials).
Results
Clinical results
After NGF treatment, significant improvements were
observed in some cognitive processes, mainly in the planning
of a communication strategy, attention and verbal compre-
hension. At the end of intranasal NGF administration, the
patient showed a substantial improvement also in facial mimi-
cry (enriched by new expressions such as joy, fear, wonder,
etc.), with an initial capacity to knit eyebrows, curl nose,
crying with tears (totally absent pretreatment), major symme-
try in the smile and more meaning to eyelids closure in
communicating. The child was also able to eat from the
mouth; in fact, some improvements were also observed in
oral motility and head rotation. At the admission in Neuro-
rehabilitation Unit and after the fourth cycle of intranasal
NGF, different functional motor scales were administered
(T0–T4). CRSHC scale (Clinical Rating Scale for Head
Control), House–Brackmann scale and Sunnybrook Facial
Grading Scale (Voluntary movement item) were tested and
Range of head Movements (ROM) was observed. CRSHC at 0
and 4 Time remained grade 0, the House–Brackmann scale
remained unchanged at grade 2. Instead the Sunnybrook
Facial Grading Scale (mouth opening) showed an improve-
ment from score 2 (initiated slight movement) at T0 to score 4
(movements almost complete) at T4. The Range of Motion
(head rotation) changed from left side Rom 9° and right side
Rom 3° at T0 to left side Rom 12° and right side Rom 6° at T4.
To detect the improvements in communicative function, a
first language test (PING ‘parole in gioco-test’) was per-
formed. The PING test is usually used to detect verbal com-
prehension using images in child with specific language
disorders or cognitive disorder (includes a score of commu-
nicative skills from 19 to 37 months). At admission (T0), the
child was not testable in relation to low attention level and the
absence of a communicative tool, while after the fourth cycle
of NGF treatment (T4) he arose a level of 37 months (max-
imum results). The child had a better relationship with his
family members and all the caregivers and was less frustrated
and in a better mood. Due to these neurological and clinical
modifications, an alternative and increasing communication
programme, involving all the family members, was started
with great success. Oral motor dyspraxia progressively
improved too, with enhanced oral motility control including
mouth opening, tongue motility, mastication and swallowing.
The ability to feed also improved and the child became able to
eat little amounts of food with a parent-reported better dis-
crimination regarding taste. In association with the improve-
ment in oral motor dyspraxia, other acquired skills, included
phonation with more explicit emission of sounds, were
observed. Moreover, during the cycles of NGF therapy, a
progressive but constant enhancement of head movements
(mainly in head lateral rotation and minimally in up and
down movements) was reported, while head support did not
improve. Some hand finger movements during play with
characteristics of voluntary control have been observed and
even improved muscular tone and tropism. Another impor-
tant amelioration was represented by the improvement in
bowel function, loosing the need for stimulation to evacuate.
The child also reacquired the cough reflex and hiccups, pre-
viously absent.
PET/CT results (for protocol used, see Supplementary
materials)
The first PET/CT study was performed 6 months after head
injury and 2 days before the beginning of intranasal NGF
administration. The others PET/CT assessments were
repeated the day after the end of each single cycle of intranasal
NGF treatment and at one-month intervals. At visual analysis,
the first PET/CT study showed a marked and global reduction
of 18F-FDG uptake in all cortical and subcortical regions in
both brain hemispheres, which was even more pronounced in
the cerebellum, suggesting a severe and diffuse glucose hypo-
metabolism (Figure 1, T0). After the first cycle of intranasal
NGF administration, a significant increase of the 18F-FDG
uptake in the majority of brain regions was evident; only in
both frontal superior regions the 18F-FDG uptake was only
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minimally increased and in the cerebellum it was almost
unchanged (Figure 1, T1). This metabolic pattern persisted
after the second and the third cycle (Figure 1, T2–T3). Finally,
after the last intranasal administration of NGF, a further
increase of the 18F-FDG uptake was evident, especially when
compared with the pretreatment PET/CT (Figure 1, T4).
These findings suggested a progressive and gradual improve-
ment of the brain glucose metabolism in all cortical and
subcortical regions with the exception of both frontal superior
regions and the cerebellum in which moderate and severe
hypometabolism persisted, respectively. All these visual find-
ings were confirmed by semi-quantitative analysis with max-
imum Standardized Uptake Value (SUV) calculated for each
right and left cerebral Volumes of Interest (VOI), as reported
in Table 1.
SPECT/CT results (for protocol used, see Supplementary
materials)
The modalities and the timing of execution of SPET/CT
assessments were the same as the PET/CT studies. Figure 2
shows the evolution of cerebral perfusion before and after the
intranasal NGF administration. The baseline SPECT/CT scan
(Figure 2, T0) revealed moderate hypoperfusion in the right
frontal cortex and a mild hypoperfusion in the right anterior
temporal and left frontal cortices, as well as in the cerebellar
hemispheres. In the second SPECT/CT scan, performed after
the first NGF treatment (Figure 2, T1), cerebral perfusion
improved slightly in the right frontal and left frontal cortices,
as well as in the right anterior temporal cortex, although it
was more impaired in both cerebellar hemispheres. In the
third and fourth SPECT/CT scans (Figure 2, T2 and T3), a
further improvement was observed in the right and left frontal
cortices and the right anterior temporal cortex. In the last
SPECT/CT scan, at the end of NGF treatment (Figure 2, T4),
the regional perfusion additionally improved in the right and
left frontal cortices, the right anterior temporal cortex, the left
occipital cortex and both cerebellar hemispheres. Visual inter-
pretation of SPECT/CT images was confirmed by a semi-
quantitative analysis, using Statistical Parametric Mapping 8
(SPM8) for co-registration and spatial normalization pur-
poses, and the mean radioactivity concentration was extracted
by automatically defined VOI placed over the grey matter of
both hemispheres and the cerebellum in normalized images.
A statistical comparison by means of Fisher’s exact test
between VOI mean activity concentrations (expressed in per-
centages) obtained at T0 and T4 SPECT/CT scans showed a
significant increase in radiotracer uptake in the right frontal
Figure 1. PET/CT study.
18F-FDG PET/CT images of brain transverse slices performed before NGF treatment (T0) and after the first (T1), the second (T2), the third (T3) and the fourth (T4) cycle
of intranasal NGF administration. A severe global reduction of 18F-FDG uptake in all cortical and subcortical regions in both brain hemispheres and, even more
pronounced, in the cerebellum (T0) was observed. After the first NGF administration, a significant increase of the 18F-FDG uptake in almost all subcortical and cortical
regions was evident: only in both frontal superior regions the 18F-FDG uptake was minimally increased and in the cerebellum it was almost unchanged (T1). After the
second and the third cycle of intranasal NGF administration, the 18F-FDG uptake in all subcortical and cortical regions remained substantially unchanged (T2, T3).
After the last administration of intranasal NGF, a further increase of the 18F-FDG uptake in all cortical and subcortical regions was evident, especially with the
pretreatment PET/CT. A severe hypometabolism in the cerebellum and a moderate hypometabolism in the frontal superior regions still persist (T4). When comparing
the last PET/CT (after the last intranasal NGF administration, T4) with the basal PET/CT (before starting the intranasal NGF administration, T0), an increase in glucose
metabolic activity of at least 50% was found in all cerebral regions; only in the right and left superior frontal lobes and in the right and left cerebellum, the glucose
metabolic activity increased by 41%, 41%, 30%, and 32%, respectively.
Table 1. Standardized Uptake Value (SUV) calculated for each right and left cerebral Volumes of Interest (VOI).
Temporal Parietal Frontal superior Frontal Occipital Cerebellum Caudate Putamen Thalamus
Time SUV Right Left Right Left Right Left Right Left Right Left Right Left Right Left Right Left Right Left
T0 SUVmax 4.53 4.39 2.46 2.16 1.99 2.03 2.76 2.87 4.28 3.94 2.89 2.75 3.67 4.14 3.01 3.15 2.58 2.41
T1 SUVmax 5.21 5.58 5.75 5.33 2.75 2.74 3.97 3.98 6.26 5.42 3.26 2.98 4.18 5.37 3.89 3.52 3.89 3.81
T2 SUVmax 7.12 7.73 6.47 7.3 2.81 2.89 5.86 5.83 6.29 6.77 3.67 3.57 5.82 6.02 4.47 4.35 4.37 4.65
T3 SUVmax 7.82 7.93 7.21 7.75 2.8 2.85 6.34 6.35 6.37 6.09 3.61 3.52 6.24 6.7 4.68 4.42 4.95 4.91
T4 SUVmax 7.54 7.07 7.79 8.03 2.81 2.88 6.16 6.69 7.4 7.89 3.76 3.65 6.52 6.66 4.73 4.75 5.14 5.45
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cortex (p = 0.01), the right anterior temporal cortex
(p = 0.007), the left occipital cortex (p = 0.01) and the right
cerebellar hemisphere (p = 0.03). Differences in VOI mean
activity concentrations between T0 and T4 measurements
failed to reach statistical significance in the left frontal cortex
(p = 0.30) and the left cerebellar hemisphere (p = 0.07).
BRAIN AND SPINAL MRI (for protocol used, see
Supplementary materials)
Figure 3 shows brain and spinal MRI assessed 6 months after
TBI. Brain parenchymal modifications before and after NGF
intranasal administration were reported. The first MRI was
performed 5 days before the beginning of intranasal NGF
treatment. The last MRI was carried out 1 week after the
end of intranasal NGF therapy. The first brain MRI showed
multiple focal traumatic lesions and haemorrhagic contusions
in the frontal and temporal cortico-subcortical regions, signs
of axonal distraction at the brainstem and at the splenium of
the corpus callosum, as consequences of TBI. Areas of
increased T2 signal and decreased T1 signal involving the
basal ganglia consistent with anoxic injury component were
also detected (Figure 3: a–c). The MRI assessment after NGF
treatment showed the evolution of the size of the ventricles
and the subarachnoid spaces, demonstrating a significant
reduction in both ventriculomegaly and subarachnoid spaces
enlargement. Moreover, the last MRI demonstrated normal
cerebral liquoral spaces (Figure 3: d, h) and the reduction of
the size of parenchymal brain lesions (Figure 3: e–g). Spinal
MRI showed post-traumatic severe spinal cord injury at the
C1–C2 level with marked thinning and hyper-intensity of
spinal cord damaged tissue; at this level Diffusion Tensor
Tractography (DTT) detected severe spinal fibre loss
(Figure 4, a–b).
EEG studies
EEG examinations performed before and after intranasal NGF
administration showed a constant and progressive reduction
in slow-wave activity with the recovery of a normal electro-
physiological rhythm (figure not shown).
Visual evoked potential studies (for protocol used, see
Supplementary materials)
Full-field 8Hz Flicker visual evoked potentials (VEPs) were
recorded at baseline and at the end of treatment according to
a previously published technique (27). Compared with base-
line, flicker VEP of both eyes showed a significant phase/
latency advance (> 90th percentile) of test-retest variability
Figure 2. SPECT/CT study.
99mTc-HMPAO SPECT/CT images before (T0) and after intranasal NGF administration (T1, T2, T3and T4). An increase in the radiotracer uptake was found in the right
frontal (+19%, p = 0.01), right anterior temporal (+35%, p = 0.007), left frontal (+8%, p = 0.30) and left occipital (+13%, p = 0.01) cortices, as well as in the right and
left cerebellar hemispheres (+18%, p = 0.03 and +12%, p = 0.07, respectively), by calculating the percentage differences in the mean activity concentration of the
selected VOIs between T0 and T4 SPECT/CT scans.
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with a shift of 60 and 100 degrees for the right and left eyes,
respectively. This shift corresponded to a response latency
advance between 20 and 30 milliseconds, indicating faster
and more efficient visual cortical responses to light after
NGF treatment. Conversely, SSEP did not show any modifi-
cations after NGF treatment (figures not shown).
NGF and DCX assay in the cerebrospinal fluid
To assess whether intranasal NGF administration modifies the
levels of soluble NGF detectable in the cerebrospinal fluid
(CSF), NGF ELISA was performed on CSF samples collected
by lumbar puncture, performed in deep sedation of the
patient, before (pretreatment) and at the end of NGF admin-
istration (see Supplementary Materials for details on treatment
protocol). As shown in Figure 5A, the NGF levels increased in
the post-treatment CSF samples (Figure 5A). Indeed, there
was a + 30% and +44% of the NGF content in the CSF after
the first and the fourth treatment, respectively. Notably, the
basal NGF levels (pretreatment values) also increased (+15%)
before the last treatment was started. It has been previously
reported that the CSF levels of the neurogenesis-associated
protein DCX increase after intraventricular NGF infusion (26)
and correlate with improved outcome in children with severe
Figure 4. Cervical spine MRI.
Sagittal T2-weighted image (a), and Diffusion Tensor Tractography (DTT) (b) showing almost complete post-traumatic severe spinal cord injury at the C1–C2 level
with marked thinning and hyper-intensity of damaged tissue; at this level DTT also showed severe fibre loss.
Figure 3. Brain MRI.
Brain MRI before (a–d) and after treatment with NGF (e–h). Axial T2w (a, e), FLAIR (b), T1w (c, g) axial images, coronal T2w (d, h) images. MRI before NGF treatment
showed areas of abnormal T2w and FLAIR hyper-intensity (a, b open arrows) and T1w hypo-intensity in the basal ganglia (c, open arrows), ventriculomegaly (d, white
arrows) and subarachnoid spaces enlargement . At the end of NGF administration, brain MRI showed a marked reduction in ventricular dilatation and normal
subarachnoid spaces (h, white arrows); parenchymal lesions appeared small in size (e, f, g, open arrows).
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TBI (28). Then, in this case study Western blot has been used
to detect the presence and variation of DCX levels in the CSF
before and after intranasal NGF administration. As depicted
in Figure 5B, DCX increased in the CSF in both the post-
treatment samples, when compared with the respective pre-
treatment controls (Figure 5B). Moreover, similar to what was
observed for NGF protein, the basal CSF content of DCX also
increased with time, as evidenced by the comparison between
the pretreatment samples.
Discussion
This case study reports about a four-year-old boy suffering
from severe TBI, tetraplegia, neurological bladder and severe
communicative and neuropsychological impairment due to
the effects of primary brain injury and prolonged cardiopul-
monary arrest. The devastating neurologic sequelae caused by
cardiac arrest and cerebral hypoperfusion have been recog-
nized since the early development of modern resuscitation
techniques (29). The persistence of unfavourable neurologic
outcome, despite advances in cardio-pulmonary resuscitation,
led the American Heart Association to recognize brain injury
after cardiac arrest as an important area for clinical research.
In the last guidelines, the term ‘cardiopulmonary-cerebral
resuscitation’ was proposed to emphasize brain injury in
relation to cardiac arrest (30). Global cerebral ischaemia dur-
ing cardiac arrest results in heterogeneous injury to the brain.
Large projection neurons of the cerebral cortex, cerebellar
Purkinje cells and the CA-1 area of the hippocampus are the
most vulnerable sites (31), whereas the subcortical areas, such
as the brainstem, thalamus and hypothalamus, are more resis-
tant to injury (32). The landmark controlled clinical trials that
primarily targeted brain injury after cardiac arrest span from
the Brain Resuscitation Clinical Trial of barbiturates in 1986
(33) to the more recent trials of therapeutic hypothermia
(29,34); however, no conclusive results have been reported in
improving the neurologic outcome in this kind of patients.
Despite advanced and up-to-date critical, neurointensive and
rehabilitative care, our patient showed no neurological
improvement 6 months after brain injury, so the child was
started on an experimental treatment with intranasal NGF
administration. Intranasal NGF treatment was followed by a
significant improvement of functional (PET/CT, SPECT/CT
and MRI) and electrophysiological (EEG and VEP) results,
with also a concomitant amelioration of the patient’s clinical
and neurological conditions, characterized by the acquisition
of voluntary movements of his legs, arms and fingers,
improved facial mimicry and phonation, attention and verbal
comprehension with consequent better interaction with his
parents and caregivers. After NGF treatment, the child
Figure 5. NGF and Doublecortin in the CSF.
The CSF content of NGF and DCX were analysed in the CSF samples collected before (pre) and after (post) the first and the last treatment period. (A) NGF content in
the CSF, measured by NGF ELISA, increased by 30% and 44% after the first and the last intranasal NGF treatment run, respectively. A 15% increase was also observed
when pretreatment samples were compared. Data expressed as pg/mL. Assays were performed in duplicate. (B) Western blot analysis of the same samples revealed
that the CSF content of DCX increased after the intranasal NGF treatments. Moreover, the comparison of the two pretreatment samples also demonstrated a
sustained basal increase of DCX induced by the first NGF treatment.
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recovered the ability to cry, cough reflex, control of oral
motility and feeding capacity, showing an improvement also
in bowel and urinary functions and, finally, making some
spontaneous respiratory efforts. It is now accepted that TBI
is the leading cause of a cascade of regenerative events that can
last for several weeks. It is possible that part of the improve-
ment in neurological conditions of the child could be
explained by the physiologic spontaneous recovery after TBI.
Many adaptive processes may begin early in the post-injury
stage and result in neuroplastic changes leading to at the
restoration of some neurological functions (35). A key role
in post-TBI recovery process seems to be related to the post-
injury oligodendrogenesis (36). Oligodendrocytes perform
many functions in the normal brain, the best known of
which is myelin production around axons; therefore, their
role is considered fundamental in post-TBI neuroplasticity
and circuitry function (37,38). This crosstalk between axons
and oligodendrocytes modulates the speed of signal conduc-
tion in an activity-dependent manner and highlights the role
that oligodendrocytes play in enhancing plasticity (39).
Therefore, it is possible that the neurologic improvement in
our patient could in part depend on this spontaneous recov-
ery, but it would have been too complicated to demonstrate
how much of this. Neuroradiological, electrophysiological and
clinical changes observed in our patient have been so remark-
able and occurred in a relatively short time that probably they
are related to NGF treatment rather than to a ‘spontaneous
recovery’. Moreover, behavioural experience has been recently
recognized as the most potent modulator of brain plasticity
after head injury, but it is possible to hypothesize that this type
of stimuli was low compared with the effects of NGF admin-
istration (40). The extensive role of the neuroprotective
mechanisms of NGF, in both central and peripheral nervous
systems, has already been widely reported, mainly as part of
neuronal damage caused by severe TBI (26,41,42). Delivering
neurotrophic factors into the brain has classically been a sig-
nificant challenge owing to the presence of the blood–brain
and blood–cerebrospinal fluid barriers limiting drug penetra-
tion into the CNS (16,43). Accumulated experience has
pointed to the existence of a direct pathway from the nose to
the brain that can facilitate the release of drugs into the CNS.
Although the exact mechanisms are not completely under-
stood yet, growing evidences suggest that these pathways
involve olfactory nerve terminations, trigeminal nerve fibres,
vascular and lymphatic pathways that allow NGF to be actively
delivered into the CNS (44,45). In experimental animal mod-
els, intranasal NGF administration showed different actions
after severe TBI, such as attenuating amyloid β42 (Aβ42)
deposits and brain oedema, inhibiting the transcription and
expression of pro-inflammatory cytokines, minimizing mito-
chondria-mediated apoptosis and, finally, reducing TBI-
induced elevation of interleukin 1β (IL-1β), thus significantly
improving the neurological outcome of the injured brain
(19,46). This patient is the first child with severe TBI to be
treated with intranasal NGF. This administration pathway
afforded higher and more persistent concentrations of NGF
in the CSF, suggesting that NGF applied on the intranasal
mucosa can readily reach the CNS, as well as the cerebral
cortex. Intranasal NGF improved cerebral perfusion and
metabolism with the consequence of concomitant ameliora-
tion of neurological functions of the child, confirming that this
neurotrophin exerts a key role in neuroprotective mechanisms
in injured brain. The specific role of NGF in determining the
mechanisms of neuronal repair in the damaged brain is not
understood yet, but some evidences support the action of this
neurotrophin in modulating DCX biosynthesis inside the
brain. New striatum neurons can be generated when NGF is
infused into the lateral ventricle of the brain and increased
levels of intrastriatal neurotrophin promote the initial phase of
induced neurogenesis (42). Previously, increased levels of both
NGF and DCX have been showed to correlate significantly
with a good outcome of patients with severe TBI (26). The
correlation between NGF and DCX suggests that both these
biological markers are involved in the mechanism of neuronal
repair after TBI, thus playing a pivotal role in neuronal con-
nection reorganization after brain insult. DCX-positive cells
were present near and among the glial scars early after brain
damage, migrating from the sub-ventricular zone towards the
cerebral cortex lesions, thus facilitating the recovery of some
cerebral functions in brain-injured patients (47). The impress-
ive results obtained in our patient, using intranasal NGF
administration, open a new potential therapeutic window not
only offering rescue treatment in children suffering from
severe TBI but also in the case of those ischaemic and neuro-
degenerative diseases responsible for the loss of neuronal
function (48). The neuroprotective effects obtained by intra-
nasal NGF are of particular importance considering the ease of
neurotrophin application via the intranasal route and the
possibility of repeating the drug administration without local
or systemic side effects.
In conclusion, this is a first step towards the development
of a larger clinical project aimed at evaluating the potential
effectiveness of intranasal NGF administration for improving
neurological outcome and clinical functions in children with
severe TBI. The current preliminary findings and the ease of
administration of the drug make it worthwhile to be investi-
gated further, mainly in head-injury patients with better base-
line neurological conditions, in order to explore more
thoroughly the benefits of NGF on cerebral function recovery.
Although further controlled, randomized, double-blind stu-
dies are needed for a better understanding of the neuropro-
tective mechanisms of this neurotrophin, intranasal NGF
administration appears to be a promising and safe rescuing
strategy for the treatment of children with neurological seque-
lae due to severe head injury. This is the first report of a non-
aggressive treatment strategy with beneficial effects on neuro-
logical functions in a child with severe TBI.
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